Articles On MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals (MXC) places its shares in a trading halt while it plans the details of an upcoming capital raising The company will remain in the halt until December 2 or when more details are released, whichever occurs first On Nov...

MGC Pharmaceuticals (MXC) completes production of the €650,000 (A$1.01 million) ArtemiC order from Swiss PharmaCan (SPC) MGC Pharma expects to receive the full amount by early December, delivering its best quarter and half-yearly revenue r...

“With the continuing outbreaks of COVID-19, not only in Europe but globally, we expect to see continued growth in the demand for COVID-19 treatments for those people who contract the disease,” says MD.

The US$750k received today is just the first part of the US$24m three-year agreement with US distributor, AMC Holdings. European-based biotech MGC Pharma (ASX:MXC) has received the full US$750k cash deposit from its US distributor AMC Holdi...

The bio-pharma group also announced that AMC has engaged Morgan Lewis & Bockius, a leading US pharmaceutical sector law firm, to seek FDA approval for its CimetrA product

Highlights Cannabis-based medicine and products businesses have expanded significantly in the past couple of years. The market is expected to grow at a CAGR of over 32.5% between 2021 to 2028. CAU, LGP, LV1, MXC are a few stocks with...

MGC Pharmaceuticals (MXC) completes the construction phase of the CimetrA production facility in Malta on schedule The company says the facility will have the capacity to produce over 20,000 units of CimetrA in liquid dose form per day – d...

The new facility in Malta sets MGC Pharma up to meet the rapidly increasing demand for its COVID-19 drug, CimetrA. Europe-based biotech MGC Pharma (ASX:MXC) is set to ramp up its manufacturing and global distribution, after completing its n...

The company is now moving onto the equipment fit-out and commissioning phase

MGC Pharmaceuticals (MXC) sees the Israeli Ministry of Health grant approval for a global dosing study for treating the effects of COVID-19 using CimetrA The company will recruit 240 patients into the study, with dosing sites in Israel, S...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is shooting higher and is currently up around 2% at 4.9 cents. Earlier in the day it was up to 5.1 cents, a gain of around 6% on the previous closing price. MGC shares have been in the gre...

The Israeli authorities will oversee the study, which will involve 240 people in three countries

MGC Pharma’s Q1 results saw the company continue to build strong foundations for future growth. Europe-based biotech MGC Pharma (ASX:MXC) has delivered another strong quarter of cash receipts and phytocannabinoid sales, as it strengthens i...

The latest quarter delivered nearly US$1mln of cash receipts and US$564,000 of Phytocannabinoid medicine sales

Early prevention of cytokine storm appears to be an effective method of treatment in mild and moderate COVID-19 cases.

MGC Pharma has secured its biggest order for any product with its US distributor AMC Holdings confident CimetrA may be the much-needed wonder drug to treat COVID-19. Europe-based biotech MGC Pharma (ASX:MXC) has secured its largest ever or...

The US$3mln purchase order is for CimetrA, MGC’s curcumin and Boswellia compound, which has shown early promise in treating the symptoms of COVID-19

The units were ordered to fast track the approval process for the medication to be distributed and sold in the US. The expedited order buoyed the market. MGC Pharmaceuticals [ASX:MXC] share price is currently up 6.90%. The post MGC Pharmac...

The initial order in the US is expected to fast track the regulatory approval for CimetrA, and establish clinical trials for MGC Pharma’s other drugs, CogniCann and CannEpil. Europe-based biotech MGC Pharma (ASX:MXC) has made crucial progre...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is clicking higher on Thursday and is currently trading at 6.1 cents. MGC shares are lifting after the company announced updates to its new production and supply agreement out of the Unit...

ShareCafeAustralia… One Hour In… ASX200 up 61 ASX200 up 61 points (0.8%) to 7258.   Commonwealth Bank (+1%); don’t forget the buy back closes tomorrow. Fortescue (+0.7%); operations at Solomon Hub have been suspended due to a significant i...

The order of 1,000 units of CimetrA is part of a landmark deal with AMC worth a minimum of US$24mln

The order of 1,000 units of CimetrA is part of a landmark deal with AMC worth a minimum of US$24mln

The research note out of fundie Canaccord says that MGC Pharma has several tailwinds, including near term revenues and clinical trials potential over the next year. UK-based wealth manager Canaccord Genuity has just initiated a speculative...

In major milestones, MGC Pharma’s non-cannabis products ArtemiC and CimetrA got further boosts today in both Germany and India which will see the products being sold in more territories. Europe-based biotech MGC Pharma (ASX:MXC) has made fu...

The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the broader ASX 200 index which rose by 0.73%. Mergers and acquisitions were very much the order of the day in the Health sector today. The countr...

Wednesday's statement brought two significant developments for the ArtemiC product group

MGC Pharmaceuticals said this marks the first time an epilepsy treatment containing THC and still undergoing clinical trials was approved by UK authorities for import.   The news saw MGC Pharmaceuticals [ASX:MXC] shares jump 10% at the time...

Europe-based biotech MGC Pharma has achieved a major milestone in its treatment of refractory epilepsy with CannEpil+ approved for import in the UK.  MGC Pharma (ASX:MXC) has been granted a landmark UK import permit for its drug CannEpil+...

MGC Pharmaceuticals Ltd is up 11.67% having achieved a new landmark for the UK cannabis market as CannEpil+, a cannabis-based treatment for epilepsy, has been approved for import by the UK authorities.

The ASX 200 health stocks index (XHJ) fell by 0.90% at the time of writing, compared to the broader ASX 200 index which fell by 0.40%. Medicinal cannabis play, Cronos Australia (ASX:CAU), has jumped by 19% in morning trading, after announci...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is charging higher on Tuesday. In early trade, the cannabis company’s shares are up 11.5% to 6.7 cents. Why is the MGC Pharma share price charging higher? Investors have been bidding the M...

Wall Street snaps four-day losing streak In US stock markets, the S&P 500 rose by 0.23% and the Dow Jones climbed 0.76% – snapping their four-day losing streak. The tech-heavy Nasdaq however, inched lower by 0.07%. Energy stocks were th...

CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months, as part of a trial.

The Boston Beer Company (NYSE:SAM) is set to launch a new range of non-alcoholic cannabis-infused drinks in Canada with the help of Australian listed Althea Group Holdings’ (ASX:AGH) subsidiary. Peak processing Solutions will research and d...

Neurological disorder specialist, Neuroscientific Biopharma (ASX:NSB), announced that research work on its lead drug EmtinB has received a tax incentive rebate under the R&D Tax Incentive program. The company said that it has been grant...

MGC Pharma has been given the green light to import its lead product CimetrA into India in a crucial step to being granted Emergency Use Authorisation to be registered as a medicine for treatment of COVID-19 patients. European-based biopha...

Revenues in the year to end June 2021 rose 43% with phytocannabanoid sales up 69%

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Hot Money Monday is typically the domain of ASX small caps, but this week saw plenty of larger companies near the top end of the list as investors responded to some reporting season surprises. Each week, Stockhead recaps ASX stocks that are...

The ASX 200 closed at 7,488 points which was 0.04% down from yesterday but up 0.37% from last Friday. The ASX Emerging Companies Index lost 0.57% to close at 2,285 points. The best sector was industrials which gained 1.07%. Tech and consume...

MGC Pharmaceuticals Ltd has been a huge winner today, up 43.59%. MXC has signed a landmark deal with an American drug distributor worth a minimum US$24 million over the next three years.